Effect of an aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the post coronary artery bypass graft trial.
White, C W; Gobel, F L; Campeau, L; Knatterud, G L; Forman, S A; Forrester, J S; Geller, N L; Herd, J A; Hickey, A; Hoogwerf, B J; Hunninghake, D B; Rosenberg, Y; Terrin, M L.
; 104(22): 2660-5, 2001 Nov 27.
Artigo em Inglês | MEDLINE | ID: mdl-11723015
Body-Weight Fluctuations and Outcomes in Coronary Disease.
Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment.
The Success Story of LDL Cholesterol Lowering.
Use of high-intensity statins for patients with atherosclerotic cardiovascular disease in the Veterans Affairs Health System: Practice impact of the new cholesterol guidelines.
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER.
LDL, HDL, VLDL, and CVD Prevention: Lessons from Genetics?
Ezetimibe in Combination With Statins Ameliorates Endothelial Dysfunction in Coronary Arteries After Stenting: The CuVIC Trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction After Coronary Stenting), a Multicenter Randomized Controlled Trial.
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
Intensive statin therapy, used alone or in combination with ezetimibe, improves homocysteine level and lipid peroxidation to a similar degree in patients with coronary artery diseases.
2018 Cholesterol Clinical Practice Guidelines: Synopsis of the 2018 American Heart Association/American College of Cardiology/Multisociety Cholesterol Guideline.